Boundless Bio (NASDAQ:BOLD) rose 85.71% on June 23, 2026, as the Serapha merger and $230 million financing reshaped the pipeline, with shares closing at $2.60.

Key Highlights

  • Rose 85.71%: Boundless Bio closed at $2.60 on June 23 after moving $1.20 per share.
  • Catalyst: During the session, the Serapha merger and $230 million financing reshaped the pipeline.
  • Company: Boundless Bio was developing oncology treatments aimed at cancers driven by extrachromosomal DNA before its announced merger.
  • Session: The stock finished at $2.60, while the available company record showed a disclosed catalyst for the move.

Boundless Bio (NASDAQ:BOLD) rose 85.71% on June 23, 2026, closing at $2.60 after a $1.20 per-share move. The session’s advance came as the Serapha merger and $230 million financing reshaped the pipeline, based on the available company disclosures and trading context.

Boundless Bio announced a definitive merger agreement with Serapha Bio in an all-stock transaction, accompanied by a concurrent $230 million private placement co-led by institutional investors. The combined company will operate as Serapha Bio, focused on advancing SERP-01, an investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency, with the combined cash expected to fund operations into the second half of 2029.

Boundless Bio was developing oncology treatments aimed at cancers driven by extrachromosomal DNA before its announced merger.

Pre-merger Boundless stockholders are expected to receive a cash dividend of approximately $44 to $48 million, while Serapha holders will own approximately 96.3% of the combined entity. Boundless Bio's existing ecDNA oncology programme was wound down after early clinical data from the KOMODO-1 trial showed insufficient pharmacokinetic exposure.

The transaction was the central corporate development behind the session. Such announcements can alter expected ownership, financing or operating focus, while completion remains governed by the disclosed terms and approvals.

The stock ended at $2.60, reflecting the market response to the announced corporate action. No additional transaction closing was recorded during the June 23 session beyond the terms described in the available announcement.

For the June 23 close, the defining facts were the 85.71% advance, the $2.60 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.